The company also appointed Pete Buzy, former President and CEO of Catalent Cell & Gene Therapy, to its Board of Directors.

AGC Biologics has partnered with Quell Therapeutics to support the development of multiple Treg cell therapy drug candidates.

The partnership combines AKBA’s industry knowledge and product expertise with PeptiSystems’ next-generation synthesizers.

Forge Biologics has entered an AAV development and manufacturing agreement to help advance Fractyl Health’s Rejuva platform.

GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready investigational specialty medicine.

Ecolab Life Sciences has opened its new US Bioprocessing Applications Laboratory in King of Prussia, Pennsylvania.

Thermo Fisher Scientific has introduced the Applied Biosystems MagMAX Pro HT NoSpin Plasmid MiniPrep Kit to address the ...

Hansa Biopharma AB has appointed Maria Törnsén as Chief Operating Officer (COO) and President U.S., effective May 19.

Xmoor Pharma has entered into a strategic partnership with KU Leuven to support a new cell and gene therapy hub.

Stylus Medicine Inc., a biotechnology company dedicated to developing transformative in vivo genetic medicines, has emerged ...

Recipharm and ProductLife Group (PLG) have joined forces to support (bio)pharmaceutical companies in accelerating time to ...

Genentech has announced plans to invest more than $700 million in a new 700,000 square foot drug manufacturing facility.